A Rare Class of New Dimeric Naphthoquinones from Diospyros lotus have Multidrug Reversal and Antiproliferative Effects by Abdur Rauf et al.
ORIGINAL RESEARCH
published: 16 December 2015
doi: 10.3389/fphar.2015.00293
Edited by:
Maria Angela Sortino,
University of Catania, Italy
Reviewed by:
Loredana Serpe,
University of Torino, Italy
Haroon Khan,
Abdul Wali Khan University Mardan,
Pakistan
*Correspondence:
Ajmal Khan
ajmalkhan@ciit.net.pk
Specialty section:
This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology
Received: 02 October 2015
Accepted: 23 November 2015
Published: 16 December 2015
Citation:
Rauf A, Uddin G, Siddiqui BS,
Molnár J, Csonka Á, Ahmad B,
Szabó D, Farooq U and Khan A
(2015) A Rare Class of New Dimeric
Naphthoquinones from Diospyros
lotus have Multidrug Reversal
and Antiproliferative Effects.
Front. Pharmacol. 6:293.
doi: 10.3389/fphar.2015.00293
A Rare Class of New Dimeric
Naphthoquinones from Diospyros
lotus have Multidrug Reversal and
Antiproliferative Effects
Abdur Rauf1, Ghias Uddin2, Bina S. Siddiqui3, Joseph Molnár4, Ákos Csonka4,
Bashir Ahmad5, Diana Szabó4, Umar Farooq6 and Ajmal Khan6*
1 Department of Geology, University of Swabi, Swabi, Pakistan, 2 Institute of Chemical Sciences, University of Peshawar,
Peshawar, Pakistan, 3 H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences,
University of Karachi, Karachi, Pakistan, 4 Department of Medical Microbiology and Immunobiology, Faculty of Medicine,
University of Szeged, Szeged, Hungary, 5 Center of Biotechnology and Microbiology, University of Peshawar, Peshawar,
Pakistan, 6 Department of Chemistry, COMSATS Institute of Information Technology, Abbottabad, Pakistan
Three new dimeric naphthoquinones, 5,4′-dihydroxy-1′-methoxy-6,6′-dimethyl-
7,3′-binaphthyl-1,4,5′,8′-tetraone (1), 5′,8′-dihydroxy-5-methoxy-6,6′-dimethyl-7,3′-
binaphthyl-1,4,1′,4′-tetraone (2) and 8,5′,8′-trihydroxy-6,6′-dimethyl-7,3′-binaphthyl-
1,4,1′,4′-tetraone (3), were isolated from the roots of Diospyros lotus. Their structures
were elucidated by spectroscopic techniques, including 1D and 2D NMR, such as
HSQC, HMBS, NOESY, and J-resolved. Compounds 1–3 were evaluated for their
effects on the reversion of multidrug resistance (MDR) mediated by P-glycoprotein
through use of the rhodamine-123 exclusion screening test on human ABCB1 gene
transfected L5178Y mouse T-cell lymphoma. Compounds 1–3 were also assessed
for their antiproliferative and cytotoxic effects on L5178 and L5178Y mouse T-cell
lymphoma lines. Both 1 and 2 exhibited promising antiproliferative and MDR-reversing
effects in a dose-dependent manner. The effects of the tested compounds on the
activity of doxorubicin were observed to vary from slight antagonism to antagonism.
Keywords: Diospyros lotus, naphthoquinones, P-glycoprotein, human ABCB1 gene transfected mouse T-cell
lymphoma, antiproliferative, MDR
INTRODUCTION
The Diospyros genus in the Ebenaceae family consists of about 500 species. This genus is
widely distributed in tropical and subtropical regions throughout the world and is native to
the Himalayan region (Uddin et al., 2011). Diospyros lotus grows up to 9 m in height in
semi-shaded areas (Uddin et al., 2014). Diospyros species are known for their multiple uses
in therapeutic and folk medicine. Diﬀerent parts of this plant are used for diﬀerent diseases:
the leaves are used to treat lumbago, the fruits as a carminative to cure biliousness, the
seeds as a sedative, and the bark as an astringent and febrifuge (Rauf et al., 2014). A leaf
extract of D. kaki (Japanese persimmon) in combination with jasmine is used in anti-tobacco
smoking candies (Uddin et al., 2013). Various triterpenoids of the lupane, oleanane, and
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FIGURE 1 | Structures of compounds 1–3.
ursane series have been isolated and proved to exhibit anti-
inﬂammatory activity (Uddin et al., 2013). Diospyros species are
used as traditional medicines, e.g., as an antifungal, to treat
hiccough, for internal hemorrhage, for bedwetting in children,
as a woman’s drug for insomnia, as an antihypertensive, to treat
dyspnea, as a vermicide and vermifuge, as a sedative, as an
antifebrile, and as a bactericide (Tezuka et al., 1973; Ganapaty
et al., 2006). AD. lotus extract and isolated compounds have been
reported to display promising antiproliferative activity (Loizzo
et al., 2009).
Quinone moieties are present in many drugs, such as
anthracyclines, daunorubicin, doxorubicin, mitomycin,
mitoxantrones, and saintopin, which are used clinically in
the therapy of solid cancer (Verma, 2006). Moreover, some
naphthoquinones isolated from Diospyros species, such as
plumbagin, exert cytotoxic activity (Padhye et al., 2012).
Multidrug resistance (MDR) is the main clinical challenge
for the active treatment of cancer (chemotherapy; Szabo and
Molnar, 1997). There are numerous mechanisms by which tumor
cells develop resistance to cytotoxic secondary metabolites. One
of them is produced by the overexpression of ATP-binding
cassette (ABC) proteins or breast cancer resistance protein
(BCRP). The ATP-binding cassette transporters represent the
largest family of transmembrane proteins that bind ATP and use
the energy to drive the transport of various molecules across
cell membranes (Gottesman and Ambudkar, 2001; Leonard
et al., 2003). ABC eﬄux transporters extrude a broad range of
amphiphilic compounds against the concentration gradient in
an energy-dependent fashion. Many of the ABC transporters
have dedicated physiological functions, and aﬀord normal tissue
protection in the brain vessels, liver, and kidney (Gottesman et al.,
2002; Sarkadi et al., 2006; Szakacs et al., 2006).
The ﬁrstly identiﬁed drug eﬄux protein was the
P-glycoprotein (P-gp, MDR1, ABCB1), encoded by the
ABCB1 gene. P-gp is composed of 1280 amino acids
(170 kDa) organized in two transmembrane domains
(Szakacs et al., 2006). This protein is overexpressed in
several human tumors and can extrude a wide range of
drugs (anticancer, antibiotics, antidepressants, antihistamines,
antiarrhythmics, immunosuppressants, HIV protease inhibitors
and steroids). Many drug molecules, such as tamoxifen,
valspodar, dexniguldipine, and tariquidar, have been proposed
to suppress the action of P-gp (Germann et al., 1993; Lopez and
Martinez-Luis, 2014).
A second cellular pump is multidrug-resistant protein 1
(MRP1, ABCC1), described in Cole et al. (1992). MRP1 is
an eﬄux pump originally discovered in doxorubicin-resistant
lung carcinoma cells displaying a multidrug resistant phenotype
without ABCB1 expression.
MRP1 is expressed ubiquitously in higher levels at the blood–
brain barrier, in the intestines and in the oral mucosa (He et al.,
2011). MRP1 expression is higher in the lungs than in any other
organ and it may have protective roles against air pollution
and inhaled toxins (Sakamoto et al., 2013). The physiological
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TABLE 1 | 13C-NMR and 1H-NMR spectral data of compound 1.
Carbon no. δC δH (mult, J, Hz)
1 184.8 –
2 140.1 6.70, d, (J = 10 Hz)
3 137.7 6.89, d, (J = 10 Hz)
4 190.3 –
5 161.8 –
6 144.0 –
7 145.5 –
8 125.7 7.27, s
9 129.4 –
10 114.1 –
11 20.6 2.01, s
12-OCH3 56.7 3.91, s
1′ 158.1 7.64, s
2′ 109.4 7.64, s
3′ 139.5 –
4′ 161.1 –
5′ 190.6 –
6′ 139.5 –
7′ 109.4 6.07, s
8′ 179.5 –
9′ 108.6 –
10′ 112.0 –
11′ 20.2 1.97, s
substrates of MRP1 include bile acids, folic acid, leukotriene
C4, and glutathione conjugates, and it confers resistance to
vincristine, methotrexate, doxorubicin, and etoposide (Cole and
Deeley, 2006; Li et al., 2008).
A third cellular pump type is BCRP, ﬁrst cloned in the drug-
resistant breast cancer cell line MCF-7 (Doyle et al., 1998).
BCRP is a half-transporter member of the ABCG subfamily
(ABCG2) with a size of 72 kDa. BCRP probably functions as
a homodimer. The expression of BCRP overlaps largely with
that of P-gp, because the protein can be found in tissues such
as the placenta, prostate, small intestine, brain, colon, liver, and
ovary (Doyle et al., 1998). Overexpression of BCRP is associated
with resistance to a wide range of diﬀerent anticancer agents:
anthracyclines, mitoxantrone, ﬂavopiridol, camptothecins, and
antifolates (Assaraf, 2006; Bihorel et al., 2007; Robey et al., 2007).
FIGURE 2 | Key HBMC correlations of compound 1.
Several studies have demonstrated the frequent occurrence of
drug eﬄux proteins in cancer tissue. Some authors have reported
signiﬁcant correlations between the overexpression of P-gp or
MRP-1 and a poor treatment response in solid tumors and some
leukemias (Brinkhuis et al., 2002; Diestra et al., 2003; Larkin et al.,
2004; Damiani et al., 2006), and a prognostic signiﬁcance for
BCRP overexpression in speciﬁc forms of leukemia (Larkin et al.,
2004).
The current study deals with the isolation of three new dimeric
naphthoquinones (1–3) from the chloroform (CHCl3) fraction of
D. lotus. The isolated compounds (1–3) were evaluated for their
eﬀects on the reversion ofMDR inmouse lymphoma and for their
antiproliferative and cytotoxic eﬀects on the L5178 and L5178Y
mouse T-cell lymphoma cell lines. A combination assay was also
applied to study the eﬀects of the drug interactions between the
dimeric naphthoquinone derivatives and the chemotherapeutic
drug doxorubicin on the MDRmouse lymphoma cell line.
MATERIALS AND METHODS
General Procedure
Melting points of compounds (1–3) were determined on a
Bicote melting point apparatus and are uncorrected. UV-visible
spectra were recorded on a Hitachi-U-3200 spectrometer,
IR spectra on an FT-IR instrument (Nicolet 380), UV-
visible spectra on a Shimadzu spectrometer, and 1H-NMR
(500 MHz), 13C-NMR (600 MHz), HMBC (600 MHz)
and HSQC (600 MHz spectra on an AVANCE AV-600
TABLE 2 | 13C-NMR and 1H-NMR spectral data of compound 2.
Carbon no. δC δH (mult, J, Hz)
1 184.6 –
2 140.1 6.70, d, (J = 10.5 Hz)
3 137.6 6.70, d, (J = 10.5 Hz)
4 190.3 –
5 161.9 –
6 146.1 –
7 148.1 –
8 121.7 7.27, s
9 130.4 –
10 114.1 –
11 20.6 1.98, s
12-OCH3 56.6 3.90, s
1′ 184.1 –
2′ 125.6 7.59, s
3′ 137.6 –
4′ 190.6 –
5′ 161.1 –
6′ 148.1 –
7′ 110.3 6.42, s
8′ 159.1 –
9′ 114.1 –
10′ 118.5 –
11′ 20.5 1.97, s
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FIGURE 3 | Key HBMC correlations of compound 2.
Cryoprob NMR instrument in CDCl3. HR-EI-MS spectra
were measured on a JEOL JMS 600H mass spectrometer;
EI source 70 eV. Normal-phase column chromatography
(CC) was performed by using silica gel (Merck). TLC was
run on pre-coated aluminum plates with silica gel 60 (F254;
Merck).
Plant Material
Diospyros lotus roots were collected from Razagram (Khall), Dir,
KPK, Pakistan, inMay 2009. The sample was authenticated byDr.
Abdur Rashid, Department of Botany, University of Peshawar,
Pakistan. A voucher specimen [Bot. 20036(PUP)] has been
deposited at the Herbarium, Department of Botany, University
of Peshawar, Pakistan.
TABLE 3 | 13C-NMR and 1H-NMR spectral data of compound 3.
Carbon no. δC δH (mult, J, HZ)
1 190.2 –
2 140.0 6.66, d, (J = 10 Hz)
3 139.9 6.89, d, (J = 10 Hz)
4 195.3 –
5 121.3 6.94, s
6 149.1 –
7 148.0 –
8 162.0 –
9 130.0 –
10 114.1 –
11-CH3 24.7 1.97, s
1′ 184.8 –
2′ 125.0 7.55, s
3′ 137.6 –
4′ 190.1 –
5′ 161.9 –
6′ 146.5 –
7′ 125.9 7.27, s
8′ 159.0 –
9′ 112.0 –
10′ 121.7 –
11′-CH3 20.7 2.01, s
FIGURE 4 | Key HMBC correlations of compound 3.
Extraction and Isolation
Shade-dried roots of D. lotus (14 kg) were powdered and
repeatedly extracted with methanol (MeOH; 64 L) at room
temperature. The extracts were combined and concentrated by
evaporating the solvent in a rotary evaporator under reduced
pressure at a temperature below 40◦C to obtain a dark red
residue (202 g). This was suspended in water and successively
partitioned into n-hexane, CHCl3, ethyl acetate (EtOAc), and
n-butanol (n-BuOH) to aﬀord n-hexane (30 g), CHCl3 (88 g),
EtOAc (20 g), and n-BuOH (50 g) fractions. The CHCl3 fraction
F-1 (30 g) was subjected to CC on silica gel (Merck silica
gel 60 (0.063–0.200 mm), 5 cm × 60 cm). The column was
eluted with n-hexane-EtOAc (100:0 → 0:100) as solvent system.
A total of 105 fractions, (RF-1 to RF-105) were obtained on
the basis of the TLC proﬁles. Fractions RF-1 to RF-10 were
combined on the basis of TLC to obtain subfraction SF-1
(2 g), which was further re-subjected to CC with n-hexane
elution to yield a reddish residue of fatty acids, while fractions
RF-11 to RF-105 were combined on the basis of the TLC
proﬁles to give major subfractions SF-3 (9.89 g) and SF-4
(3.98 g).
Fraction SF-4 (9.89 g) was subjected to CC with n-hexane-
EtOAc (100:0 → 10:15) elution and 60 fractions were obtained
and combined on the basis of the TLC proﬁles, yielded two
major fractions MF-1 (5.44 g) and MF-2 (3.41 g). Fraction MF-1
(5.44 g) was subjected to preparative TLC silica gel (Merck
silica gel 60 F254), using n-hexane-EtOAc (85:15, RF: 0.45;
84:16, RF: 0.46; 80:20, RF: 0.47), which furnished three new
dimeric naphthoquinones: 5,4′-dihydroxy-1′-methoxy-6,6′-
dimethyl-7,3′-binaphthyl-1,4,5′ ,8′-tetraone (1), 5′,8′-dihydroxy-
5-methoxy-6,6′-dimethyl-7,3′-binaphthyl-1,4,1′ ,4′-tetraone (2)
and 8,5′,8′-trihydroxy-6,6′-dimethyl-7,3′-binaphthyl-1,4,1′ ,4′-
tetraone (3) (Figure 1). The structure elucidation of these new
TABLE 4 | Antiproliferative effects of compounds 1–3 on the L5178Y
mouse T-cell lymphoma cell line.
Compounds IC50 (μg/ml) SEM
1 0.05 0.004
2 0.046 0.005
3 0.26 0.01
SEM, standard error of the mean.
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FIGURE 5 | Cytotoxic effects of dimeric naphthoquinones on PAR and
MDR mouse. T-cell lymphoma cell lines. The mean IC50 was calculated on
the basis of the results of three independent experiments. SEM, standard
error of the mean.
compounds was based on spectroscopic analysis, including 1D
and 2D NMR.
Anticancer Assays
Cell Cultures
L5178 mouse T-cell lymphoma cells (ECACC cat. no. 87111908,
U.S. FDA, Silver Spring, MD, USA) were transfected with
pHa MDR1/A retrovirus, as previously described (Cornwell
et al., 1987; Bak et al., 1989). The MDR1-expressing cell
line L5178Y was selected by culturing the infected cells with
colchicine. L5178 (parent) mouse T-cell lymphoma cells and the
human MDR1-transfected subline were cultured in McCoy’s 5A
medium supplemented with 10% heat-inactivated horse serum,
200 mM L-glutamine, and a penicillin-streptomycin mixture in
100 U/L and 10 mg/L concentrations, respectively. MDR was
detected with a monoclonal antibody (Bak et al., 1989; Molnar
et al., 1999). The cell lines were incubated in a humidiﬁed
atmosphere (5% CO2, 95% air) at 37◦C. The L5178 mouse T-cell
lymphoma cells (PAR; ECACC Cat. No. 87111908, obtained
from FDA, Silver Spring, MD, USA) were transfected with
pHa MDR1/A retrovirus, as previously described by Cornwell
et al. (1987). The ABCB1-expressing cell line L5178Y (MDR)
was selected by culturing the infected cells with colchicine
(Cornwell et al., 1987). L5178 (parent) mouse T-cell lymphoma
cells and the L5178Y human ABCB1-transfected subline were
cultured in McCoy’s 5A medium supplemented with 10% heat-
inactivated horse serum, 200 mM L-glutamine and a penicillin-
streptomycin mixture in concentrations of 100 U/L and 10 mg/L,
respectively.
TABLE 5 | Cytotoxic effects of dimeric naphthoquinones on PAR and MDR
mouse T-cell lymphoma cell lines.
Compounds Mean IC50 (μg/mL)
PAR SEM MDR SEM
1 2.15 0.41 4.49 0.17
2 2.82 0.50 3.93 0.10
3 3.59 0.15 6.29 1.94
SEM, standard error of the mean.
TABLE 6 | Effects of compounds 1–3 on the reversal of multidrug
resistance in mouse lymphoma cells in the presence of low doses (0.1–1
μg/mL).
Compounds Concentration
(μg/mL)
FSC SSC FL-1 FAR MF-1
Verapamil 10 1993 613 10 10.5 12
1 0.1 2003 606 1.63 1.72 0.673
1 1982 619 10.1 10.63 17.2
2 0.1 2008 609 1.05 1.1 0.806
1 2024 582 1.24 1.3 0.698
3 0.1 2029 606 1.1 1.15 0.806
1 2013 636 0.801 0.84 0.673
DMSO 2% v/v 2108 604 0.782 0.82 0.604
FSC, forward scatter count of cells in the samples (cell size ratio); SSC, side scatter
count of cells in the samples; FL-1, mean fluorescence intensity of the cells; FAR,
fluorescence activity ratio; MF-1, maximum fluorescence intensity.
Antiproliferative Assays
The antiproliferative eﬀects of compounds 1–3 were determined
in 96-well ﬂat-bottomed microtiter plates (Molnar et al., 2004b;
Gyemant et al., 2005). The antiproliferative potentials of the
compounds were tested at a concentration of 1 μg/mL, using
the L5178Y mouse T-cell lymphoma MDR cell line in the
experimental model. The cells were distributed into 96-well ﬂat-
bottomed microtiter plates at a concentration of 100 μL in
McCoy’s 5A or RPMI-1640 medium. For the antiproliferative
assay, 6 × 103 mouse T-cell lymphoma cells in 100 μL of
medium were added to each well. The culture plates were
further incubated at 37◦C for 72 h for the antiproliferative eﬀect
assay. At the end of the incubation period, 20 μL of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT;
Sigma, St. Louis, MO, USA) solution (from a 5 mg/mL stock)
was added to each well. After 4 h, 100 μL of 10% sodium dodecyl
sulfate (SDS; Sigma) in 0.01 M HCl was added to each well. The
culture plates were further incubated at 37◦C overnight. The cell
growth was determined by measuring the optical density (OD) at
550 nm (ref. 630 nm) with aMultiscan EX ELISA reader (Thermo
Labsystem, Cheshire, WA, USA). In the assay, the solvent did not
have any eﬀect on the cell growth at the concentrations used for
half-maximal inhibitory concentration (IC50) calculations. IC50
values and the standard error of the mean (SEM) of triplicate
experiments were calculated by using GraphPad Prism software
version 5.00 forWindows with non-linear regression curve ﬁtting
(GraphPad Software, San Diego, CA, USA1).
Assays for Cytotoxic Effects
The eﬀects of increasing concentrations of the drugs alone on
cell growth were tested in 96-well ﬂat-bottomed microtiter plates.
The compounds were diluted in 100 μL of medium. 1 × 104
mouse T-cell lymphoma cells (PAR orMDR) in 50μL of medium
were then added to each well, with the exception of the medium
control wells. The culture plates were further incubated at 37◦C
for 24 h; at the end of the incubation period, 15 μL of MTT
solution (from a 5 mg/mL stock) was added to each well. After
1www.graphpad.com
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TABLE 7 | Types of interaction between dimeric naphthoquinone
derivatives and doxorubicin in MDR mouse T-cell lymphoma cell line.
Compounds Ratio ED50 CI Interaction
1 1.724:25
1.724:25
0.862:50∗
1.85494
1,77987
1,66629
1.302 Moderate antagonism
2 6.897:25∗
3.448:50
0.862:50
1.24794
1.65175
1.66558
1.175 Slight antagonism
3 6.897:50
3.448:50
3.448:100∗
2.36396
2.49152
1.80217
1.459 Antagonism
CI, combination index. ∗Best ratio.
incubation at 37◦C for 4 h, 100 μL of SDS solution (10% in
0.01 M HCI) was added to each well and the plates were further
incubated at 37◦C overnight. The cell growth was determined
by measuring the OD at 540 nm (ref. 630 nm) with a Multiscan
EX ELISA reader (Thermo Labsystems, Cheshire, WA, USA). In
the assay, the solvent did not have any eﬀect on the cell growth
at the concentrations used for IC50 calculations. IC50 values
and the SEM of triplicate experiments were calculated by using
GraphPad Prism software version 5.00 for Windows with non-
linear regression curve ﬁtting (GraphPad Software, San Diego,
CA, USA2).
Assays for Reversal of MDR in Mouse
Lymphoma Cells
The L5178Y MDR and L5178 parent cell lines were grown
in McCoy’s 5A medium containing 10% heat-inactivated horse
serum, supplemented with L-glutamine and antibiotics. The cells
were adjusted to a density of 2 × 106 mL, resuspended in serum-
free McCoy’s 5A medium and distributed in 0.5 mL aliquots
into Eppendorf centrifuge tubes. The tested compounds were
added at 0.1–1 μg/mL ﬁnal concentrations, and the samples
were incubated for 10 min at room temperature. Verapamil was
applied as positive control (Cornwell et al., 1987) in 10 μg/mL
concentration. Next, 10 μL (5.2 μM ﬁnal concentration) of
the indicator rhodamine 123 (Sigma, St Louis, MO, USA) was
added to the samples and the cells were incubated for a further
20 min at 37◦C, washed twice and resuspended in 0.5 mL
of PBS for analysis. The ﬂuorescence of the cell population
was measured with a Partec CyFlow ﬂow cytometer (Munster,
Germany). Verapamil was used as a positive control in the
rhodamine 123 exclusion experiments (Gruber et al., 1988).
The tested compounds were dissolved in DMSO, which was
also used as solvent control. The percentage mean ﬂuorescence
intensity was calculated for the treated MDR and parental cell
lines as compared with the untreated cells. The activity ratio was
calculated via the following equation (Molnar et al., 2004a) on the
basis of the measured ﬂuorescence values:
FAR = MDRtreated/MDRcontrol
parentaltreated/parentalcontrol
2www.graphpad.com
The results presented were obtained from a representative ﬂow
cytometric experiment in which 105 individual cells of the
population were evaluated for the amount of rhodamine 123
retained. The data were analyzed with FlowJo software3.
Checkerboard Combination Assays
A checkerboard microplate method was applied to study
the eﬀects of the drug interactions between the dimeric
naphthoquinone derivatives and the chemotherapeutic drug
doxorubicin on the MDR mouse lymphoma cell line. The
dilutions of doxorubicin were made in a horizontal direction
in 100 μL, and the dilutions of the dimeric naphthoquinone
compounds were made vertically in the microtiter plate in 50 μL.
The cells were resuspended in culture medium and distributed
into each well in 50 μL containing 6 × 103 PC3 MDR mouse
T-cell lymphoma cells. The plates were incubated for 72 h at
37◦C in a CO2 incubator. The cell growth rate was determined
after MTT staining, as described above. The combination index
(CI) values at 50% growth inhibition (ED50) were determined by
using CompuSyn software4 (ComboSyn, Inc., Paramus, NJ. USA)
to plot 4 or 5 data points for each ratio. CI values were calculated
bymeans of the median-eﬀect equation (Chou andMartin, 2005),
where CI< 1, CI= 1, and CI> 1 represent synergism, an additive
eﬀect (or no interaction) and antagonism, respectively.
RESULTS AND DISCUSSION
The whole MeOH extract was suspended in water and
successively partitioned with n-hexane, CHCl3, EtOAc, and
n-BuOH. The CHCl3 fraction was selected for phytochemical
investigation due to the presence of a greater amount of
compounds as indicated by the TLC proﬁle. CC of the CHCl3
fraction (30 g) on silica gel resulted in the isolation of three
new dimeric naphthoquinones (1–3). The structures of these
compounds were elucidated by spectroscopic techniques and
comparisons with literature data.
Compound 1 was isolated as a yellow amorphous powder. It
exhibited the molecular ion peak at m/z; 404.2100 a.m.u. (calcd.
404.2101) corresponding to the molecular formula C23H16O7.
The IR spectrum showed absorption bands at 3550 cm−1 for
OH stretching, 2924 cm−1 for CH stretching, 1643 cm−1 for
CO stretching and 1634, 160, and 1460 cm−1 for CH aromatic
stretching. The UV spectrum exhibited absorptions at 253, 296,
and 435 nm.
1D and 2D NMR studies were carried out to elucidate the
structure of the compound. The assignments of protons and
carbons were carried out by HMBC, HMQC, 1H-1H-COSY and
J-resolved experiments (Table 1). The 1H-NMR spectrum of
1 revealed the presence of two tertiary methyl groups (s, δH
2.01, 1.97, 2 × 3H), a methoxy group (s, δH 3.91, OCH3), three
quinoid protons centered at d, δH 6.70, J = 10 Hz, H-2; d, 6.89,
J = 10 Hz, H-3; s, 6.07, H-7′), and two aromatic protons (s, δH
7.27, H-8; s, 7.64, H-2′). The 13C-NMR (BB and DEPT) spectra
3www.ﬂowjo.com
4http://www.combosyn.com
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(Table 1) exhibited signals of 23 carbons: two methyl carbons,
one methoxy carbon, and 20 carbons for two naphthoquinone
units. The quinoid protons resonated as a doublet at δH 6.70 (H-
2) and 6.89 (H-3), showing HMBC correlations with δC 184.8
(C-1) and 190.3 (C-4). The aromatic proton (s, δH 7.27) exhibited
correlations with δC 129.4 (C-9) and 114.1 (C-10), while that at
s, δH 7.64 showed correlations with δC 158.1 (C-1′), 179.5 (C-8′),
and 108.6 (C-9′). All the assignments were made with the help of
HMBC correlations, as shown in Figure 2.
The spectral data identify compound 1 as 5,4′-dihydroxy-
1′-methoxy-6,6′-dimethyl-7,3′-binaphthyl-1,4,5′ ,8′-tetraone, as a
new secondary metabolite.
Compound 2 was isolated as a yellow amorphous powder. Its
HRMS exhibited the molecular ion peak at m/z 404.2100 (calcd:
404.2101), consistent with the molecular formula C23H16O7.
The IR spectrum displayed absorption bands at 3560 cm−1
for OH stretching, 2925 cm−1 for CH stretching, 1644 cm−1
for C = O stretching and 1603 cm−1 for aromatic proton
stretching. The UV spectrum exhibited absorption peaks at 253,
299, and 432 nm. The protons and carbons were assigned out
by HMBC, HMQC, 1H-1H-COSY, and J-resolved experiments
(Table 2). The 1H-NMR spectrum of compound 2 showed the
presence of two tertiary methyl groups (s, δH 1.98 and 1.97),
one methoxy group (s, δH 3.90, OCH3), three quinoid protons
(d, δH 6.70, J = 10.5 Hz, H-2; d, δH 6.89, J = 10.5 Hz, H-3;
s, δH 6.42, H-7′) two aromatic protons (s, δH 7.27, H-8, and
s, 7.59, H-2′). The 13C-NMR (BB and DEPT) spectra (Table 2)
exhibited 23 carbon signals for two methyl carbons, one methoxy
carbon, and 20 carbons for two naphthoquinone moieties. The
quinoid protons at δH 6.70 (H-2) and 6.70 (H-3) showed
strong HMBC correlations with δC 184.6 (C-1) and 190.3 (C-
4), respectively. The aromatic proton centered at δH 7.27 (H-8)
revealed correlations with δC 130.4 (C-9) and 114.1 (C-9′), while
the quinoid proton at δH 7.59 (H-2′) showed HMBC correlations
with δC 184.1 (C-1) and 137.6 (C-3). The aromatic proton at δH
6.42 (H-7′) exhibited correlations with δC 159.1 (C-8′), 114.1 (C-
9′), and 184.1 (C-1). All substituents were assigned with the help
of HMBC correlations as shown in Figure 3. Compound 2 was
characterized on the basis of the spectral data as 5′,8′-dihydroxy-
5-methoxy-6,6′-dimethyl-7,3′-binaphthyl-1,4,1′ ,4′-tetraone.
Compound 3 was puriﬁed as a yellow amorphous powder. Its
HRMS exhibited the molecular ions peak atm/z 390.0001 (calcd.
390.0007), consistent with the molecular formula C22H14O7. The
IR spectrum displayed absorption bands at 3550 cm−1 (OH
stretching), 2988 cm−1 (CH stretching), 1642 cm−1 (C = O
stretching) and 1602 cm−1 (CH aromatic stretching). The UV
spectrum exhibited absorption peaks at 250, 301, and 436 nm.
The protons and carbons were assignment by HMBC, HMQC,
1H-1H-COSY, and J-resolved experiments (Table 3). The 1H-
NMR spectrum of 3 showed proton signals indicating the
presence of two tertiary methyl groups resonating at δH 1.97 (s,
H-11) and 2.01 (s, H-11′), three quinoid protons at δH 6.66 (d,
J = 10 Hz, H-2), 6.89, (d, J = 10 Hz, H-3), and δH 6.94 (s, H-5),
and two aromatic proton singlets centered at δH 7.55 (H-2′), and
δH 7.27 (H-7′). The 13C-NMR (BB and DEPT) spectra (Table 3)
exhibited the resonances of 22 carbons, identiﬁed as two methyl
carbons and 20 carbons for two naphthoquinone moieties. The
quinoid proton signals (δH 6.66, H-2; 6.89, H-3 and 7.55, H-2′)
showedHMBC (Figure 4) correlations with δC 190.2 (C-1), 195.3
(C-4), 137.6 (C-3′), and 190.1(C-4′), while the aromatic proton
signals (δH 6.94, H-5 and 7.27 H-5) correlated with δC 24.7 (C-
11), 159.0 (C-8′) and 112.0 (C-9′), respectively. On the basis of the
spectral data, compound 3 is characterized as 8,5′,8′-trihydroxy-
6,6′-dimethyl-7,3′-binaphthyl-1,4,1′ ,4′-tetraone.
Dimeric naphthoquinones 1–3 were investigated for their
potential properties as MDR eﬄux pump modulators. They were
ﬁrst screened for antiproliferative activity on human ABCB1
gene transfected mouse lymphoma cell line L5178Y, which
speciﬁcally overexpresses a membrane-localized transporter (P-
gp, ABCB1). In order to test the potential clinical application of
compounds 1–3, they were evaluated as concerns the reversal
of MDR (Csonka et al., 2013). The antiproliferative eﬀects
of compounds 1–3 were determined by the MTT method.
Compounds 1 and 2 showed promising antiproliferative potential
on the L5178Ymouse T-cell lymphoma cell line, with IC50 values
of 0.05 ± 0.004 μg/mL and 0.046 ± 0.005 μg/mL, respectively,
whereas compound 3 had an IC50 value of 0.26 ± 0.01 μg/mL
(Table 4).
The cytotoxic eﬀects of the dimeric naphthoquinones on the
PAR andMDR cell lines were studied. Evaluation of the cytotoxic
activities of the compounds revealed that 1 and 3 were the most
active against the parental mouse T-lymphoma cell line, with IC50
values of <3 μg/mL. Both of these compounds were also active
against the MDR cell line (Figure 5 and Table 5).
Compounds 1–3 were also evaluated for the reversion of
the MDR of ABCB1 gene transfected mouse lymphoma cell
line, followed by ﬂow cytometry, which measures intracellular
accumulation of rhodamine 123, a ﬂuorescent substrate analog of
epirubicin. The ﬂuorescence activity ratio (FAR) value was used
to evaluate the ABCB1 transporter modulating potential. When
the tested compounds were investigated in concentrations of 0.1
to 1 μg/mL by ﬂow cytometry (Table 6), the side scatter count
and forward scatter count values increased, indicating that the
compounds exerted membrane eﬀects and the granulation of the
cytoplasm was increased. The results revealed a special type of
toxic eﬀect on the reversal of MDR at toxic doses of 1 μg/mL.
The FAR of compounds 1–3 diﬀered: compound 1 proved to
be a very eﬀective MDR modulator, while compounds 2 and 3
did not exhibit signiﬁcant eﬀects in a short-time experiment.
Verapamil, a calcium channel blocker and chemosensitizer, was
used as a positive control. The results relating to MDR reversal
activity in the current investigation are presented in Table 6. On
MDR mouse lymphoma cells, compounds 1–3 were screened in
two concentrations (1 and 0.1 μg/mL). Compound 1 was a fairly
moderate modulator of the eﬄux pump activity (FAR = 1.72
at 1 μg/mL and 10.63 at 0.1 μg/mL), while compounds 2
(FAR = 1.1 at 1 μg/mL and 1.3 at 0.1 μg/ml) and 3 (FAR = 1.15
at 1 μg/mL and 0.84 at 0.1 μg/mL) were somewhat weaker
(Table 6).
The eﬀects of the tested compounds on the activity of
doxorubicin were observed to vary from slight antagonism to
antagonism as shown in Table 7.
The tested dimeric naphthoquinones 1–3 display several
structural diﬀerences, mainly relating to the positions of the
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aromatic linkages. Compound 3 diﬀerences from compounds
1 and 2 in containing an extra hydroxyl group rather than
a methoxy substituent. It is clear that the joint presence of
methoxy and hydroxy groups enhanced the activity (Table 4).
The positions of quinone moieties inﬂuenced the eﬄux pump
activity, as demonstrated by the FAR values in Table 6.
CONCLUSION
Three new dimeric naphthoquinones (1–3) isolated from
the CHCl3-soluble fraction of the roots of D. lotus, led to
the reversal of MDR and exerted antiproliferative activity.
They also exhibited promising antiproliferative eﬀects in
a dose-dependent manner on two cancer cell lines. This
discovery strengthens our belief in the indigenous knowledge
of traditional health cures against cancer diseases. The
results suggest that research on naphthoquinone derivatives
could possibly lead to the discovery of potent anticancer
agents.
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